News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pipex Pharmaceuticals (PPXP) to Host Conference Call at 10:15am ET Wednesday July 9th to Discuss Phase II Clinical Trial Results in Dry Age-Related Macular Degeneration (AMD) With Oral Z-Monocys



7/9/2008 8:35:41 AM

ANN ARBOR, MI--(Marketwire - July 08, 2008) - Pipex Pharmaceuticals, Inc. (AMEX: PP), a specialty pharmaceutical company developing innovative late-stage drug candidates for the treatment of central nervous systems and autoimmune diseases, today announced that it will hold a conference call on Wednesday, July 9, 2008 at 10:15 a.m. ET to discuss the results of its double-blind, placebo-controlled phase II clinical trial results in the treatment of dry age-related macular degeneration (AMD) with oral Z-Monocys. Nicholas Stergis, Vice Chairman and Chief Executive Officer of Pipex, will host the call.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES